Pipeline-focused public companies
Find biotechnology and pharmaceutical companies by market profile and drug-development maturity, then open each ticker for its stock, pipeline and catalyst research page.
| Company | Price | Market cap | Pipeline | Next catalyst | Open |
|---|---|---|---|---|---|
| AA AAPGAscentage Pharma | $17.00-1.8% | $1.59B | 14 assetsStage unavailable | No dated catalyst | |
| AA AARDAardvark Therapeutics | $6.82+15.8% | $149.3M | 2 assetsPhase 3 | ARD-101Phase 3 · Data readout | |
| AB |
The screener is the parent research index for individual ticker pages such as CAPR. Filter the biotech company universe here, then open a company to review its stock snapshot, drug assets, clinical stage and dated catalysts. Quote information is a cached market snapshot and may be delayed.
| $264.96+1.2% |
| $468.22B |
64 assetsPDUFA |
SKYRIZI/Risankizumab (N/A) (IL-23 Inhibitor)PDUFA · Approval decision |
| AB ABCLAbCellera | $11.32-2.2% | $3.67B | 4 assetsPhase 2 | ABCL575Phase 1 · Data readout |
| AB ABEOAbeona Therapeutics | $6.09+2.2% | $348.3M | 5 assetsStage unavailable | No dated catalyst |
| AB ABOSAcumen Pharmaceuticals | $3.16-0.9% | $228.5M | 4 assetsPhase 2 | Sabirnetug (ACU193)Phase 2 · Data readout |
| AB ABSIAbsci | $9.55+2.9% | $1.64B | 3 assetsPhase 1/2 | ABS-201Phase 1/2 · Data readout |
| AB ABUSArbutus Biopharma Corporation | $5.21+9.2% | $1.03B | 6 assetsStage unavailable | No dated catalyst |
| AB ABVXAbivax | $114.95-2.7% | $10.03B | 2 assetsPhase 2b | ObefazimodPhase 2b · Data readout |
| AC ACADACADIA Pharmaceuticals | $29.50+1.6% | $5.08B | 9 assetsPhase 2 | ACP-204Phase 2 · Data readout |
| AC ACERAcer Therapeutics | $0.66-17.9% | — | 3 assetsStage unavailable | No dated catalyst |
| AC ACETAdicet Bio | $9.19-2.0% | $86.0M | 6 assetsPhase 1 | ADI-001 (allogeneic CAR gamma-delta T cell therapy)Phase 1 · Data readout |
| AC ACHVAchieve Life Sciences | $7.99-0.4% | $822.2M | 2 assetsStage unavailable | No dated catalyst |
| AC ACIUAC Immune SA | $2.90+9.8% | $288.3M | 11 assetsPhase 2 | ACI-7104.056Phase 2 · Data readout |
| AC ACLXArcellx Inc | $115.07+0.0% | $6.73B | 4 assetsPDUFA | Anito-cel (anitocabtagene autoleucel)(CART-ddBCMA)PDUFA · Approval decision |
| AC ACOGAlpha Cognition | $9.75+2.6% | $212.3M | 1 assetsStage unavailable | No dated catalyst |
| AC ACRSAclaris Therapeutics Inc. | $6.41+1.3% | $943.5M | 12 assetsPhase 2 | ATI-052Phase 1b · Data readout |
| AC ACTUActuate Therapeutics | $1.27+3.3% | $30.5M | 7 assetsStage unavailable | No dated catalyst |
| AC ACXPAcurx Pharmaceuticals | $1.47+1.4% | $6.3M | 2 assetsStage unavailable | No dated catalyst |
| AD ADAGAdagene Inc | $4.02-1.7% | $265.6M | 8 assetsPhase 2 | Neoadjuvant Muzastotug (ADG126)Phase 2 · Data readout |
| AD ADAPAdaptimmune Therapeutics | $0.05-15.1% | $14.6M | 2 assetsStage unavailable | No dated catalyst |
| AD ADCTADC Therapeutics | $1.00+3.8% | $127.2M | 12 assetsPhase 3 | ZYNLONTA (Loncastuximab Tesirine) (CD19)Phase 2 · Data readout |
| AD ADILAdial Pharmaceuticals | $6.22+5.3% | $16.3M | 3 assetsStage unavailable | No dated catalyst |
| AD ADMAADMA Biologics | $9.84+0.8% | $2.20B | 3 assetsStage unavailable | No dated catalyst |
| AD ADPTAdaptive Biotechnologies Corporation | $25.99+2.2% | $4.15B | 2 assetsStage unavailable | No dated catalyst |
| AD ADVMAdverum Biotechnologies Inc. | $4.36+0.0% | $96.3M | 2 assetsPhase 3 | Ixoberogene soroparvovec (Ixo-vec) (ADVM-022) (AAV.7m8-aflibercept)Phase 3 · Data readout |
| AD ADXNAddex Therapeutics | $4.94+8.1% | $6.3M | 5 assetsStage unavailable | No dated catalyst |
| AF AFMDAffimed N.V. | $0.18+0.0% | — | 7 assetsStage unavailable | No dated catalyst |
| AG AGENAgenus Inc. | $8.09+8.0% | $364.1M | 21 assetsPhase 2 | Botensilimab/Balstilimab (AGEN1181/AGEN2034) (CTLA-4/PD-1 Blockade)Phase 2 · Data readout |
| AG AGIOAgios Pharmaceuticals Inc. | $33.09-1.6% | $1.98B | 12 assetsApproved | PYRUKYND (Mitapivat)PDUFA · Approval decision |
| AG AGMBAgomab | $13.25-1.3% | $652.5M | 3 assetsPhase 2 | Ontunisertib (AGMB-129)Phase 2 · Data readout |
| AG AGRXAgile Therapeutics | $1.51+0.0% | — | 2 assetsStage unavailable | No dated catalyst |
| AG AGTCApplied Genetic Technologies Corporation | $0.39+0.0% | — | 3 assetsStage unavailable | No dated catalyst |
| AK AKBAAkebia | $0.91-1.4% | $251.2M | 6 assetsPhase 2 | AKB-9090 (HIF-PH Inhibitor)Phase 1 · Data readout |
| AK AKROAkero Therapeutics | $54.65+0.0% | $4.50B | 4 assetsStage unavailable | No dated catalyst |
| AK AKTSAktis Oncology | $24.07+0.3% | $1.34B | 3 assetsPhase 1b | [225Ac]Ac-AKY-1189 (AKY-1189)Phase 1b · Data readout |
| AK AKTXAkari Therapeutics | $7.85+0.8% | $15.3M | 8 assetsStage unavailable | No dated catalyst |
| AL ALCAlcon | $73.63+1.0% | $35.59B | 4 assetsStage unavailable | No dated catalyst |
| AL ALDXAldeyra Therapeutics Inc. | $1.52+1.3% | $91.7M | 14 assetsStage unavailable | No dated catalyst |
| AL ALECAlector Inc. | $2.36+4.4% | $263.5M | 9 assetsStage unavailable | No dated catalyst |